Mostrar el registro sencillo del ítem
A plasma fatty acid profile associated to type 2 diabetes development: from the CORDIOPREV study
dc.contributor.author | Villasanta-González, Alejandro | |
dc.contributor.author | Alcalá Díaz, Juan Francisco | |
dc.contributor.author | Vals-Delgado, Cristina | |
dc.contributor.author | Arenas, Antonio Pablo | |
dc.contributor.author | Cardelo, Magdalena P. | |
dc.contributor.author | Romero-Cabrera, Juan Luis | |
dc.contributor.author | Rodríguez-Cantalejo, Fernando | |
dc.contributor.author | Delgado-Lista, Javier | |
dc.contributor.author | Malagón, María M. | |
dc.contributor.author | Pérez-Martínez, Pablo | |
dc.contributor.author | Schulze, Matthias B. | |
dc.contributor.author | Camargo García, A. | |
dc.contributor.author | López-Miranda, José | |
dc.date.accessioned | 2021-11-02T11:54:43Z | |
dc.date.available | 2021-11-02T11:54:43Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | http://hdl.handle.net/10396/22010 | |
dc.description.abstract | Purpose: The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. For this reason, it is essential to identify biomarkers for the early detection of T2DM risk and/or for a better prognosis of T2DM. We aimed to identify a plasma fatty acid (FA) profile associated with T2DM development. Methods: We included 462 coronary heart disease patients from the CORDIOPREV study without T2DM at baseline. Of these, 107 patients developed T2DM according to the American Diabetes Association (ADA) diagnosis criteria after a median follow-up of 60 months. We performed a random classification of patients in a training set, used to build a FA Score, and a Validation set, in which we tested the FA Score. Results: FA selection with the highest prediction power was performed by random survival forest in the Training set, which yielded 4 out of the 24 FA: myristic, petroselinic, α-linolenic and arachidonic acids. We built a FA Score with the selected FA and observed that patients with a higher score presented a greater risk of T2DM development, with an HR of 3.15 (95% CI 2.04–3.37) in the Training set, and an HR of 2.14 (95% CI 1.50–2.84) in the Validation set, per standard deviation (SD) increase. Moreover, patients with a higher FA Score presented lower insulin sensitivity and higher hepatic insulin resistance (p < 0.05). Conclusión: Our results suggest that a detrimental FA plasma profile precedes the development of T2DM in patients with coronary heart disease, and that this FA profile can, therefore, be used as a predictive biomarker. | es_ES |
dc.format.mimetype | application/pdf | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.rights | https://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.source | European Journal of Nutrition 61, 843-857 (2022) | es_ES |
dc.subject | Type 2 diabetes | es_ES |
dc.subject | Disease prediction | es_ES |
dc.subject | Fatty acids | es_ES |
dc.subject | COX | es_ES |
dc.subject | FA Score | es_ES |
dc.title | A plasma fatty acid profile associated to type 2 diabetes development: from the CORDIOPREV study | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | https://doi.org/10.1007/s00394-021-02676-z | es_ES |
dc.relation.projectID | Gobierno de España. AGL2014-53417-R | es_ES |
dc.relation.projectID | Gobierno de España. PCIN-2016-084 | es_ES |
dc.relation.projectID | Gobierno de España. PIE14/00005 | es_ES |
dc.relation.projectID | Gobierno de España. PIE14/00031 | es_ES |
dc.relation.projectID | Gobierno de España. AGL2015-67896-P | es_ES |
dc.relation.projectID | Gobierno de España. CP14/00114 | es_ES |
dc.relation.projectID | Gobierno de España. DTS19/00007 | es_ES |
dc.relation.projectID | Instituto de Salud Carlos III. PI13/00023 | es_ES |
dc.relation.projectID | Instituto de Salud Carlos III. PI19/00299 | es_ES |
dc.relation.projectID | Instituto de Salud Carlos III. PI16/01777 | es_ES |
dc.relation.projectID | Junta de Andalucía. CVI-7450 | es_ES |
dc.relation.projectID | Instituto de Salud Carlos III. CP14/00114 | es_ES |
dc.relation.projectID | Instituto de Salud Carlos III. CPII19/00007 | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |